FDA grants RPDD to META Pharmaceuticals’ hyperoxaluria drug
The US FDA has granted rare paediatric disease designation for META Pharmaceuticals’ META-001-PH to treat primary hyperoxaluria.
The US FDA has granted rare paediatric disease designation for META Pharmaceuticals’ META-001-PH to treat primary hyperoxaluria.
What's Your Reaction?
